Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome
Published in: Journal of Clinical Medicine
Access to document
10.3390/jcm8060763
document
Objectives: Primary Sjogren syndrome (SS) is diagnosed based on the American European Consensus Group (AECG) criteria, but lacks specificity, not only in the involvement of salivary glands, but also in extra-glandular involvement. Whole-body somatostatin receptor scintigraphy with Tc-99m-HYNIC-TOC scintigraphy could overcome these limitations. The aims of this study were to evaluate salivary gland uptake of Tc-99m-HYNIC-TOC in untreated patients with de-novo diagnosis of SS as compared to control subjects and as compared to conventional sialoscintigraphy with (TcO4-)-Tc-99m. We also aimed to evaluate the involvement of joints. Methods: Tc-99m-HYNIC-TOC...
Luz Kelly Anzola, Jose Nelson Rivera, Rudi A. Dierckx, Chiara Lauri, Stefano Valabrega, Filippo Galli, Sergio Moreno Lopez, Andor W. J. M. Glaudemans, Alberto Signore
The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans
Published in: EJNMMI Research
Access to document
10.1186/s13550-019-0514-9
document
Conjugation or fusion to AlbudAbs (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and extravascular organ concentrations of AlbudAbs in humans, we studied tissue distribution and elimination of a non-conjugated Zr-89-labeled AlbudAb in healthy volunteers using positron emission tomography/computed tomography (PET/CT).MethodsA non-conjugated AlbudAb (GSK3128349) was radiolabeled with Zr-89 and a single 1mg (similar to 15MBq) dose intravenously administered to eight healthy males. Zr-89-AlbudAb tissue distribution was followed for up to...
Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom, Marie Davies
Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology
Published in: Journal of Clinical Medicine
Access to document
10.3390/jcm8050681
document
Background: Molecular nuclear medicine plays a pivotal role for diagnosis in a preclinical phase, in genetically susceptible patients, for radio-guided surgery, for disease relapse evaluation, and for therapy decision-making and follow-up. This is possible thanks to the development of new radiopharmaceuticals to target specific biomarkers of infection, inflammation and tumour immunology. Methods: In this review, we describe the use of specific radiopharmaceuticals for infectious and inflammatory diseases with the aim of fast and accurate diagnosis and treatment follow-up. Furthermore, we focus on specific oncological indications with an emphasis...
Alberto Signore, Chiara Lauri, Sveva Auletta, Kelly Anzola, Filippo Galli, Massimiliano Casali, Annibale Versari, Andor W. J. M. Glaudemans
Tc-99m-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study
Published in: EJNMMI Research
Access to document
10.1186/s13550-019-0511-z
document
RATIONALE: Acute allograft rejection is one of the major complications after lung transplantation, and adequate and early recognition is important. Till now, the reference standard to detect acute rejection is the histopathological grading of transbronchial biopsies (TBBs). Acute rejection is characterised by high levels of activated T lymphocytes. Interleukin-2 (IL-2) binds specifically to high-affinity IL-2 receptors expressed on the cell membrane of activated T lymphocytes. The aim of this proof-of-concept study was to evaluate if non-invasive imaging with 99mTc-HYNIC-IL-2 is able to detect acute rejection after lung transplantation....
Performance characteristics and quantitative clinical evaluation of the digital Siemens Biograph Vision PET/CT